Abstract
Protein kinases are one of the most targeted protein families in current drug discovery pipelines. They are implicated in many oncological, inflammatory, CNS-related and other clinical indications. Virtual screening is a computational technique with a diverse set of available tools that has been shown many times to provide novel starting points for kinase-directed drug discovery. This review starts with a concise overview of the function, structural features and inhibitory mechanisms of protein kinases. In addition to briefly reviewing the practical aspects of structure-based virtual screenings, we discuss several case studies to illustrate the state of the art in the virtual screening for type I, type II, allosteric (type III-V) and covalent (type VI) kinase inhibitors. With this review, we strive to provide a summary of the latest advances in the structure-based discovery of novel kinase inhibitors, as well as a practical tool to anyone who wishes to embark on such an endeavor.
Keywords: Drug discovery, Kinase, Structure-based virtual screening, Inhibitor, Docking, DFG motif, Activation segment, hinge, Covalent docking.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
Volume: 17 Issue: 20
Author(s): David Bajusz, Gyorgy G. Ferenczy and Gyorgy M. Keseru*
Affiliation:
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok korutja 2, Budapest 1117,Hungary
Keywords: Drug discovery, Kinase, Structure-based virtual screening, Inhibitor, Docking, DFG motif, Activation segment, hinge, Covalent docking.
Abstract: Protein kinases are one of the most targeted protein families in current drug discovery pipelines. They are implicated in many oncological, inflammatory, CNS-related and other clinical indications. Virtual screening is a computational technique with a diverse set of available tools that has been shown many times to provide novel starting points for kinase-directed drug discovery. This review starts with a concise overview of the function, structural features and inhibitory mechanisms of protein kinases. In addition to briefly reviewing the practical aspects of structure-based virtual screenings, we discuss several case studies to illustrate the state of the art in the virtual screening for type I, type II, allosteric (type III-V) and covalent (type VI) kinase inhibitors. With this review, we strive to provide a summary of the latest advances in the structure-based discovery of novel kinase inhibitors, as well as a practical tool to anyone who wishes to embark on such an endeavor.
Export Options
About this article
Cite this article as:
Bajusz David, Ferenczy G. Gyorgy and Keseru M. Gyorgy*, Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery, Current Topics in Medicinal Chemistry 2017; 17 (20) . https://dx.doi.org/10.2174/1568026617666170224121313
DOI https://dx.doi.org/10.2174/1568026617666170224121313 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Connexin Genes as Promising Therapeutic Targets in Cancers
Current Pharmacogenomics The Anti-Tumor Mechanism and Target of Triptolide Based on Network Pharmacology and Molecular Docking
Recent Patents on Anti-Cancer Drug Discovery Is There An Association Between Vitamin D and Hypertension?
Recent Patents on Cardiovascular Drug Discovery Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design The Challenge of Exploiting ABCG2 in the Clinic
Current Pharmaceutical Biotechnology Concepts of Egr-1 Activation – A Hub for Signal Transduction Cascades
Current Signal Transduction Therapy Birt-Hogg-Dubé Syndrome, a Genodermatosis that Increases Risk for Renal Carcinoma
Current Molecular Medicine Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells
Current Cancer Drug Targets ADAM8 in Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Genetically Modified Dendritic Cells for Cancer Immunotherapy
Current Gene Therapy AGE-RAGE System and Carcinogenesis
Current Pharmaceutical Design Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Bioactive Polyphenols from Healthy Diets and Forest Biomass
Current Nutrition & Food Science Bleomycin Induced Sensitivity to TRAIL/Apo-2L-Mediated Apoptosis in Human Seminomatous Testicular Cancer Cells is Correlated with Upregulation of Death Receptors
Anti-Cancer Agents in Medicinal Chemistry The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine Molecular Chaperone Hsp90 as a Target for Oxidant-Based Anticancer Therapies
Current Medicinal Chemistry